All News

Across rural US community pharmacies, researchers explore the common barriers and facilitators to pneumococcal vaccine uptake.

The FDA clears Hepcludex, the first chronic hepatitis D therapy, offering new hope with strong viral suppression data and key safety monitoring needs.

Two separate bills were marked up in House committees last week and were officially advanced to potentially move additional PBM reform into law.

CMS pares Medicare Star Ratings, pushing patient-driven outcomes, medication safety, costs, and quality of life, reshaping how Part D plans compete.

Exploring pneumococcal vaccination rates among eligible adult patients, researchers conducted a quality improvement initiative at a clinic in Illinois.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

Late-phase trials show switching to daily oral orforglipron or lower-dose tirzepatide helps maintain weight loss, easing regain and boosting adherence.

Researchers hope to inform national strategies on pharmacists’ potential place in asthma management.

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Results of Eli Lilly’s investigational triple agonist were reported in the TRIUMPH-1 Phase 3 clinical trial.

New FDA guidance sharpens postmarket pregnancy drug safety data, improving labels and empowering pharmacists to report adverse events.

Although currently contained outside of the US, the Bundibugyo strain of the virus reached an American worker in the Democratic Republic of Congo.

New OASIS 4 data show early oral semaglutide responders hit 21.6% weight loss and improve mobility.

In part 2, Tom DePietro, PharmD, explores emerging topics of interest within community pharmacy, including AI, PBMs, and the industry’s evolving nature.

Heat waves can alter drug safety and storage, and some medicines raise heat risk.

The announcement comes with a partnership with Mark Cuban Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.

With Commissioner Makary resigning just days prior, this marks the second and third major change in the federal agency’s leadership this month.

Between clinical initiatives, educational strategies, and regulatory frameworks, researchers explore PGx services integration.

The approval also includes an interchangeability designation, meaning both products can be substituted at the pharmacy level.

FDA approves Baxfendy, a new oral aldosterone blocker, to help hard-to-control hypertension.

Despite a myriad of data and news releases about the growing prominence of AI in pharmacy practice, several knowledge and acceptance gaps persist.

Oral ensitrelvir given within 72 hours cuts household symptomatic COVID-19 by 67%, showing safe postexposure prevention.

Meta-analysis shows empagliflozin is superior to sitagliptin with metformin for glycemic control.

HHS targets SSRI overuse, urging pharmacists and clinicians to reassess long-term therapy, use safer tapers, and expand nondrug care.

As health officials respond to ongoing concerns, Nathan Ott, PharmD, joined to discuss key hantavirus facts that pharmacists can relay to their communities.

Among both childhood and adult populations, researchers assess the quality of life across a large cohort of patients reporting pneumococcal disease cases.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.